p53 status and the efficacy of cancer therapy in vivo

Science

Volumn 266, Issue 5186, 1994, Pages 807-810

  Lowe, Scott W ^a   Bodis, Stephan ^b   Mcclatchey, Andrea ^a   Remington, Lee ^a   Ruley, H Earl ^c   Fisher, David E ^d   Housman, David E ^a   Jacks, Tyler ^e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; PROTEIN P53;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; EXPERIMENTAL NEOPLASM; GAMMA RADIATION; GENE EXPRESSION; GENE MUTATION; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

ANIMAL; APOPTOSIS; DOXORUBICIN; DRUG RESISTANCE; FIBROSARCOMA; GAMMA RAYS; GENES, P53; IMMUNOCOMPROMISED HOST; MICE; MICE, NUDE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; RADIATION TOLERANCE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

ANIMALIA;

EID: 0027944206     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.7973635     Document Type: Article

References (20)